Fluicell AB brings inspiration and innovation to life-science researchers around the globe, redefining the approach to cell biology, and drug discovery.
The company is a world leader and pioneer in open-volume microfluidics for the life sciences, and holds a strong IP and patent position with five different patent families in the estate.
Fluicell’s existing products are the research tools Biopen® and Dynaflow® Resolve, which today allow researchers to investigate the effects of drugs on individual cells at a unique level of detail.
As a further development of Fluicell’s existing product portfolio, the company is developing a unique high-resolution bioprinting technology in both 2D and 3D under the name Biopixlar™ Retina. With this system, complex tissue-like structures can be created where positioning of individual cells can be controlled.
Fluicell is a public company founded in 2012, and is based in Gothenburg, Sweden.